J&J pitches its S1P1 MS drug into the regulatory ring as the competition heats up fast
The S1P1 rivalry in the multiple sclerosis arena is about to heat up substantially.
Six months after beating out Aubagio in a head-to-head study, J&J has teed up its marketing application for ponesimod. If approved the drug, a big prize in their $30 billion Actelion buyout, will go up against Novartis’ rival Mayzent as well as ozanimod from Bristol Myers — which is facing a looming PDUFA date.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.